High-throughput single-cell activity-based screening and sequencing of antibodies using droplet microfluidics
Annabelle Gérard,Adam Woolfe,Guillaume Mottet,Marcel Reichen,Carlos Castrillon,Vera Menrath,Sami Ellouze,Adeline Poitou,Raphaël Doineau,Luis Briseno-Roa,Pablo Canales-Herrerias,Pascaline Mary,Gregory Rose,Charina Ortega,Matthieu Delincé,Sosthene Essono,Bin Jia,Bruno Iannascoli,Odile Richard-Le Goff,Roshan Kumar,Samantha N. Stewart,Yannick Pousse,Bingqing Shen,Kevin Grosselin,Baptiste Saudemont,Antoine Sautel-Caillé,Alexei Godina,Scott McNamara,Klaus Eyer,Gaël A. Millot,Jean Baudry,Patrick England,Clément Nizak,Allan Jensen,Andrew D. Griffiths,Pierre Bruhns,Colin Brenan
DOI: https://doi.org/10.1038/s41587-020-0466-7
IF: 46.9
2020-03-30
Nature Biotechnology
Abstract:Mining the antibody repertoire of plasma cells and plasmablasts could enable the discovery of useful antibodies for therapeutic or research purposes1. We present a method for high-throughput, single-cell screening of IgG-secreting primary cells to characterize antibody binding to soluble and membrane-bound antigens. CelliGO is a droplet microfluidics system that combines high-throughput screening for IgG activity, using fluorescence-based in-droplet single-cell bioassays2, with sequencing of paired antibody V genes, using in-droplet single-cell barcoded reverse transcription. We analyzed IgG repertoire diversity, clonal expansion and somatic hypermutation in cells from mice immunized with a vaccine target, a multifunctional enzyme or a membrane-bound cancer target. Immunization with these antigens yielded 100–1,000 IgG sequences per mouse. We generated 77 recombinant antibodies from the identified sequences and found that 93% recognized the soluble antigen and 14% the membrane antigen. The platform also allowed recovery of ~450–900 IgG sequences from ~2,200 IgG-secreting activated human memory B cells, activated ex vivo, demonstrating its versatility.
biotechnology & applied microbiology